Original news and analysis on international IP policy
The World Health Organization last week released a new report highlighting how global and local research can help design a system for universal health coverage tailored to each country’s specific needs.
The Medicines Patent Pool today announced an agreement with Swiss pharmaceutical company Roche to increase access and reduce the cost of a medicine that treats a viral infection in people with weakened immune systems, specifically for people living with HIV.
World Health Organization members are meeting this week to advance the new international mechanism against substandard and counterfeit medicines.
Just as the world of international intellectual property law and policy is ever-changing, so are the faces within it. Below you will find an updated list of the latest people news and IP moves across international organisations, national and regional governments, nonprofit organisations, and the private sector, from the first half of this year.
Decline in pharmaceutical research and development productivity is one of the main challenges addressed in the 2013 edition of the World Health Organization report, Priority Medicines for Europe and the World. Whether the decline in pharmaceutical R&D is due to R&D depletion, overly strict regulatory hurdles, or the current pharmaceutical business model remains unanswered.
The themes of innovation, collaboration, and policy coherence shared the spotlight during panel discussions at the 5 July technical symposium on Medical Innovation: Changing Business Models. The event was jointly hosted by the World Health Organization, World Intellectual Property Organization, and World Trade Organization.
The leaders of three top international organisations in Geneva last week discussed synergies in public health and called for increased collaboration and creativity to move medical innovation out of its quagmire of inefficiency. The opening session was marked by the head of the World Health Organization urging stakeholders to develop mechanisms to separate drug prices from costs of research and development. And the head of the GAVI Alliance, in the keynote address, discussed how patent thickets could impede access to vaccines.
An analysis of available information indicates that research-oriented product development partnerships (PDPs) are seen as providing a better approach to neglected diseases than most other public-private partnerships. Yet, in spite of many positive results, PDPs still have a limited impact in developing countries.
The price of first- and second-line anti-retrovirals (ARVs) have declined due to increased generic competition, while third-line regimens remain “exorbitantly priced,” according to the latest edition of a publication from Médecins Sans Frontières (MSF).
The World Health Organization (WHO) has issued new recommendations that call for earlier HIV treatment with antiretroviral therapy (ART) in an effort to keep HIV patients healthier for a longer period of time.